Ask AI
Overcoming Obstacles in Obesity

CE / CME

Breaking Barriers in Obesity Care: Applying Emerging Evidence to Primary Care Practice

Physician Assistants/Physician Associates: 1.00 AAPA Category 1 CME credit

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: maximum of 1.00 AMA PRA Category 1 Credit

Nurse Practitioners/Nurses: 1.00 Nursing contact hour

Released: December 10, 2025

Expiration: December 09, 2026

Activity

Progress
1 2 3
Course Completed

Introduction

In this module, Dr Christopher Weber explores how to translate recent developments in obesity care into clinical practice. Highlights include discussion of how to apply new definitions of obesity and corresponding diagnostic criteria. Dr Weber also discusses new evidence on incretin-based antiobesity medications (AOMs) like semaglutide and tirzepatide, including their efficacy on obesity-related conditions and comorbidities in specific populations. Finally, Dr Weber explores emerging AOMs, including new formulations of current therapies and novel agents.

The key points discussed in this module are illustrated with thumbnails from the accompanying downloadable PowerPoint slidesets, which can be downloaded here or by clicking any of the slide thumbnails in the module alongside the expert commentary.

Decera Clinical Education plans to measure the educational impact of this activity. Some questions will be asked twice: once at the beginning of the activity and then once again after the discussion that informs the best choice. Your responses will be aggregated for analysis, and your specific responses will not be shared.

Before continuing with this educational activity, please take a moment to answer the following questions.

Your patient has obesity and multiple cardiometabolic risk factors. Their primary goal is reducing cardiometabolic risk, and they would like to know which metrics are best for assessing this. How would you advise them?

Your patient is considering an incretin-based therapy for obesity management. They have cardiovascular (CV) risk factors but no established cardiovascular disease (CVD). They’d like to know whether an incretin-based therapy could help prevent CV events. What would you tell them?

Your patient is receiving tirzepatide 10 mg/wk for obesity management and treatment of obstructive sleep apnea (OSA). After 1 yr, they have met their weight loss goal of 10% and experienced some OSA improvement. You have discussed increasing the dose to 15 mg/wk because it is associated with greater weight loss in more people. Your patient wants to know if this would also help with their OSA. What do you tell them?

How many people with obesity do you provide care for in a typical week?

For those who practice in academic or community settings, please indicate your practice setting: